These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28967699)

  • 1. The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure.
    Okabe T; Yakushiji T; Kido T; Oyama Y; Igawa W; Ono M; Ebara S; Yamashita K; Yamamoto MH; Saito S; Amemiya K; Isomura N; Ochiai M
    ESC Heart Fail; 2018 Feb; 5(1):87-94. PubMed ID: 28967699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
    Brisco-Bacik MA; Ter Maaten JM; Houser SR; Vedage NA; Rao V; Ahmad T; Wilson FP; Testani JM
    J Am Heart Assoc; 2018 Sep; 7(18):e009149. PubMed ID: 30371181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of short-acting loop diuretic doses and cardiac sympathetic nerve abnormalities on outcomes of patients with reduced left ventricular function.
    Onitsuka H; Koyama S; Ideguchi T; Ishikawa T; Kitamura K; Nagamachi S
    Medicine (Baltimore); 2019 Feb; 98(8):e14657. PubMed ID: 30813209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry.
    Kapelios CJ; Laroche C; Crespo-Leiro MG; Anker SD; Coats AJS; Díaz-Molina B; Filippatos G; Lainscak M; Maggioni AP; McDonagh T; Mebazaa A; Metra M; Moura B; Mullens W; Piepoli MF; Rosano GMC; Ruschitzka F; Seferovic PM; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1424-1437. PubMed ID: 32237110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
    DeVore AD; Hasselblad V; Mentz RJ; O'Connor CM; Armstrong PW; McMurray JJ; Ezekowitz JA; Tang WH; Starling RC; Voors AA; Califf RM; Hernandez AF
    Eur J Heart Fail; 2015 Mar; 17(3):340-6. PubMed ID: 25619549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure.
    Woodruff AE; Kelley AM; Hempel CA; Loeffler WJ; Echtenkamp CA; Hassan AK
    Ann Pharmacother; 2016 Jun; 50(6):437-45. PubMed ID: 26956954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.
    Fudim M; O'Connor CM; Mulder H; Coles A; Bhatt AS; Ambrosy AP; Kraus WE; Piña IL; Whellan DJ; Mentz RJ
    Am Heart J; 2018 Nov; 205():133-141. PubMed ID: 30158057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
    Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
    Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis.
    Täger T; Fröhlich H; Grundtvig M; Seiz M; Schellberg D; Goode K; Kazmi S; Hole T; Katus HA; Atar D; Cleland JGF; Agewall S; Clark AL; Frankenstein L
    Int J Cardiol; 2019 Aug; 289():83-90. PubMed ID: 30827731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis.
    Yilmaz MB; Gayat E; Salem R; Lassus J; Nikolaou M; Laribi S; Parissis J; Follath F; Peacock WF; Mebazaa A
    Eur J Heart Fail; 2011 Nov; 13(11):1244-52. PubMed ID: 22024466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD).
    Hamaguchi S; Kinugawa S; Tsuchihashi-Makaya M; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Circ J; 2012; 76(8):1920-7. PubMed ID: 22665070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
    Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
    JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).
    Mentz RJ; Hasselblad V; DeVore AD; Metra M; Voors AA; Armstrong PW; Ezekowitz JA; Tang WH; Schulte PJ; Anstrom KJ; Hernandez AF; Velazquez EJ; O'Connor CM
    Am J Cardiol; 2016 Feb; 117(3):404-11. PubMed ID: 26704029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure.
    Laliberte B; Reed BN; Devabhakthuni S; Watson K; Ivaturi V; Liu T; Gottlieb SS
    J Card Fail; 2017 Oct; 23(10):746-752. PubMed ID: 28688888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Discharged Loop Diuretic Dose to Home Dose on Hospital Readmissions in Patients with Acute Decompensated Heart Failure: A Retrospective Cohort Study.
    Alshibani M; Alshehri S; Alyazidi W; Alnomani A; Almatruk Z; Almeleebia T
    Heart Surg Forum; 2020 Jul; 23(4):E470-E474. PubMed ID: 32726210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazide diuretics versus loop diuretics in stage 3-5 CKD: impact on cardiorenal outcomes.
    Sung LC; Chiu HW; Yu SM; Tsou LL; Hsu YH; Wu MS; Lin CL; Tsai FJ; Chou CL
    Postgrad Med; 2024 Sep; 136(7):738-748. PubMed ID: 39189768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.